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A lthough hypoglycemia is the mostcommon side effect of insulin ther-apy in diabetes and its morbidity is
well known, for many years, the poten-
tially life-threatening effects of hypogly-
cemia on the cardiovascular (CV) system
have either been overlooked or have been
dismissed as inconsequential to people
with insulin-treated type 2 diabetes. This
scenario may possibly be a consequence
of the persisting misconception that this
population is seldom exposed to severe
hypoglycemia, deﬁned as any episode
that requires external assistance for re-
covery, whereas self-treated events are
classiﬁed as “mild” (1). This myth was
ﬁrmly repudiated by the ﬁndings of the
large prospective study by the U.K.
Hypoglycemia Study Group (2), which
demonstrated that severe hypoglycemia
is a common problem in insulin-treated
type 2 diabetes and that the incidence
increases with duration of insulin ther-
apy. However, evidence for CVmorbidity
associated with hypoglycemia has been
predominantly hypothetical and anec-
dotal (1,3). The potential dangers of in-
tensive treatment regimens and strict
glycemic control in people with type 2
diabetes who have CV disease (CVD)
have now been highlighted by the dis-
concerting outcomes of recent studies
(4–6), in which hypoglycemia was im-
plicated in the excess mortality that was
observed in some of these trials. It is
therefore timely to review the effects of
hypoglycemia on the CV system, how
this major metabolic stress could pre-
cipitate major vascular events such as
myocardial infarction and stroke, and
its potential role in these recent clinical
studies.
PHYSIOLOGICAL EFFECTS OF
HYPOGLYCEMIA—In the adult hu-
man, acute hypoglycemia causes pro-
nounced physiological responses as a
consequence of autonomic activation,
principally of the sympatho-adrenal sys-
tem, and results in end-organ stimulation
and a profuse release of epinephrine
(adrenaline). This profound autonomic
stimulus provokes hemodynamic changes,
the important consequences of which are
to maintain the supply of glucose to the
brain and promote the hepatic production
of glucose. Blood ﬂow is therefore in-
creased to the myocardium, the splanch-
nic circulation (to provide precursors of
gluconeogenesis to the liver), and the
brain. The hemodynamic changes associ-
ated with hypoglycemia include an in-
crease in heart rate and peripheral systolic
blood pressure, a fall in central blood
pressure, reduced peripheral arterial re-
sistance (causing a widening of pulse
pressure), and increased myocardial con-
tractility, stroke volume, and cardiac out-
put (7). The workload of the heart is
therefore temporarily but markedly in-
creased. This transient cardiac stress is
unlikely to be of serious functional impor-
tance in healthy young people who have a
normal CV system, but may have danger-
ous consequences in many older people
with diabetes, especially individuals with
type 2 diabetes, many of whom have cor-
onary heart disease.
In nondiabetic people, the arteries
become more elastic during acute hypo-
glycemia with a decline in arterial wall
stiffness, but in people with type 1 di-
abetes of .15 years’ duration, arterial
wall stiffness per se is greater and arteries
are less elastic in response to hypoglyce-
mia, manifesting in a lesser fall in central
arterial pressure (8). Normal elasticity of
the arterial wall ensures that the reﬂected
pressure wave from the high-pressure ar-
terioles, generated during each myocar-
dial contraction, returns to the heart
during early diastole, so enhancing coro-
nary arterial perfusion, which occurs
mainly during diastole. However, pro-
gressive stiffening of the arterial walls (as
occurs in most people with longstanding
diabetes) accelerates the return of the
reﬂected wave causing its earlier arrival
during late systole. This pathophysiolog-
ical effect may interfere with coronary
arterial perfusion and promote myocar-
dial ischemia.
Hypoglycemia has long been known
to affect the electrocardiogram (ECG) (9),
causing ST wave changes with lengthen-
ing of the QT interval (10) and cardiac
repolarization (11). Both experimentally
induced and spontaneous clinical hypo-
glycemic episodes prolong cardiac repo-
larization, the process whereby the heart
prepares for coordinated contraction dur-
ing diastole and where abnormalities in
other conditions can increase the risk of
cardiac arrhythmias. These changes are
reﬂected by changes in the T wave of the
electrocardiogram (Fig. 1). Hypoglycemia
leads to reduction in its amplitude with
ﬂattening and lengthening of the T wave
(3), which is quantiﬁed by measuring the
length of the QT interval (mathematically
corrected for the prevailing heart rate
[QTc]). Electrophysiological changes are
related to hypokalemia, which is a conse-
quence of the profuse secretion of cate-
cholamines. These changes may increase
the risk of cardiac arrhythmia; various ab-
normal heart rhythms, including ventric-
ular tachycardia and atrial ﬁbrillation,
have been reported during hypoglycemia.
This phenomenon and its contribution to
causing sudden death after hypoglycemia
are discussed in detail below.
The increased sympathetic activity
and concurrent secretion during hypo-
glycemia of other hormones and pep-
tides such as the potent vasoconstrictor,
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endothelin, also have pronounced effects
on intravascular hemorheology, coagula-
bility, and viscosity. Increased plasma
viscosity occurs during hypoglycemia be-
cause of an increase in erythrocyte concen-
tration, whereas coagulation is promoted
by platelet activation and an increment in
factor VIII and von Willebrand factor (7).
Endothelial function may be compromised
during hypoglycemia because of an in-
crease in C-reactive protein and the mobi-
lization and activation of neutrophils and
platelet activation. These changes may
promote intravascular coagulation and
thrombosis and encourage the develop-
ment of tissue ischemia, with the myocar-
dium being potentially vulnerable.
HYPOGLYCEMIA-INDUCED
CV EVENTS—Anecdotal case reports
have indicated a temporal relationship
between severe hypoglycemia, acute vas-
cular events, and sudden death (3,7).
Case reports describe angina in associa-
tion with acute hypoglycemia and acute
coronary syndromes with typical ECG
and enzyme changes after severe hypogly-
cemia (3). When hypoglycemia was in-
duced in six subjects with type 2
diabetes, ﬁve developed ischemic ECG
changes, whereas a bradyarrhythmia re-
sulted in loss of consciousness in another
patient (12). When continuous glucose
measurements and Holter ECG monitor-
ing were performed simultaneously in pa-
tients with type 2 diabetes and known
ischemic heart disease, 54 episodes of hy-
poglycemia (blood glucose level ,3.9
mmol/L [70 mg/dL]) were identiﬁed, 10
of which were accompanied by chest pain
(13). This illustrates the difﬁculty of dem-
onstrating that a major cardiac event has
been provoked by acute hypoglycemia in
any individual diabetic patient, since si-
multaneous glucose and ECGmonitoring
is rarely possible in clinical practice.
SUDDEN DEATH IN
YOUNG PEOPLE WITH
TYPE 1 DIABETES—A link between
hypoglycemia and sudden death was
raised in the 1960s, but the ﬁrst detailed
description appeared in 1991 after in-
vestigation of a series of deaths of young
adults with type 1 diabetes (14). The sur-
vey was commissioned by the British
Diabetic Association after concern that
insulin of human origin might cause
fatal hypoglycemia. After deaths from
deﬁnite causes were excluded, the au-
thors identiﬁed 22 individuals with type
1 diabetes aged ,50 years, who despite
being previously well had a very similar
manner of death. Most were found lying
in an undisturbed bed, a scenario that
prompted the label “dead in bed syn-
drome” (15). These observations have
been followed by several epidemiological
surveys that have conﬁrmed both the
mode of death and its increased frequency
in individuals with type 1 diabetes (16–
18). An autopsy study from Australia (19)
suggested that sudden unexpected deaths
are four times more frequent than in a
comparable nondiabetic population and,
of these, many are found dead in an un-
disturbed bed.
HYPOGLYCEMIA AS A
POTENTIAL RISK FACTOR
FOR SUDDEN
DEATH IN DIABETES—Cumulat-
ing clinical and experimental evidence
has shown that hypoglycemia can cause
abnormal electrical activity in the heart
and has strengthened the premise that
hypoglycemia can provoke sudden death.
High-resolution electrocardiography,
which measures the QT interval pre-
cisely, in conjunction with hypoglycemic
clamps to control the depth of hypo-
glycemia, has demonstrated lengthening
of the QT interval both in diabetic and
nondiabetic individuals (20,21). Clinical
episodes of hypoglycemia have been
shown to cause QT lengthening, mea-
sured using ambulatory ECG monitoring
and simultaneous measurement of blood
glucose (by either intermittent venous
sampling or continuous glucose monitor-
ing) (22).
Activation of the sympathoadrenal
system probably drives these changes.
Epinephrine infusion increases QT inter-
vals (23), and b-blocking drugs attenuate
QT lengthening during experimental hy-
poglycemia (24). However, hypoglyce-
mia induces a fall in serum potassium
via sympathoadrenal activation and a di-
rect effect of insulin, and hypoglycemia
per se may have an effect by directly in-
hibiting cardiac ion channels that are re-
sponsible for potassium efﬂux during
cardiac repolarization (25).
RELEVANCE OF ABNORMAL
CARDIAC REPOLARIZATION
AND LENGTHENED QT
INTERVAL TO CARDIAC
ARRHYTHMIAS—In other situations,
lengthening of the QT interval is a strong
predictor of sudden death. The long QT
syndrome is a congenital condition caused
by mutations within the genes that code for
proteins comprising the voltage-gated ion
channels contributing to the cardiac action
Figure 1—Typical QT measurement with a screen cursor placement from a subject during eu-
glycemia (left panel), showing a clearly deﬁned Twave, and hypoglycemia (right panel), showing
prolonged repolarization and a prominent U wave. Reproduced from Marques et al. (20) with
permission from John Wiley & Sons.
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potential. Those affected have abnormal
cardiac repolarization represented by pro-
longed QT on their electrocardiograms and
an increased risk of sudden death due to
cardiac arrhythmias (26). QT lengthening
caused by certain therapeutic agents in-
cluding antihistamines or antibiotics in
susceptible individuals can also cause
sudden cardiac death. Because hypoglyce-
mia is common and sudden death is rare,
abnormal cardiac repolarization alone
cannot explain why hypoglycemia might
lead to sudden death. Other factors that
might contribute include inherited muta-
tions or polymorphisms of genes involved
in cardiac electrical activity and acquired
abnormalities of other potentially relevant
pathological mechanisms such as auto-
nomic neuropathy.
POTENTIAL ROLE OF CARDIAC
AUTONOMIC NEUROPATHY—It
is possible that an interaction between
hypoglycemia-induced abnormalities of
cardiac repolarization and autonomic neu-
ropathy contributes to the risk of sudden
death in individuals with diabetes. Di-
abetic autonomic neuropathy is known
to be associated with an increased mortal-
ity, and resting QT intervals are generally
longer in patients with autonomic neu-
ropathy than in patients without (27). The
recent demonstration that brief periods
of experimental hypoglycemia impair
CV autonomic function for up to 16 h is
additional evidence for a clinically relevant
interaction (28).
However, not all data are supportive,
since individuals with diabetic autonomic
neuropathy actually have smaller incre-
ments inQT intervals during experimental
hypoglycemia than individuals without
(29). The apparent paradox relates to the
diminished sympathoadrenal responses
that are observed both in patients with
neuropathy (in part related to a long du-
ration of diabetes) and after repeated epi-
sodes of hypoglycemia. Thus, on the one
hand, a combination of autonomic neu-
ropathy (aggravated by antecedent hypo-
glycemia) and then a severe episode
leading to a powerful sympathoadrenal
response might substantially increase the
risk of arrhythmia-provoked sudden
death, whereas on the other hand, re-
peated hypoglycemia in a person with
impaired sympathoadrenal responses
and longstanding diabetes might be pro-
tective. The way in which these different
factors interact to confer risk is poorly
understood and requires further experi-
mental work.
CASE REPORTS OF
HYPOGLYCEMIA-
ASSOCIATED ARRHYTHMIA—
The numerous case reports of cardiac
arrhythmias provoked by spontaneous
hypoglycemia (7) emphasize the clinical
relevance of the association, particularly
since ethical considerations limit experi-
mental studies in this area. Those reported
range fromsevere sinus bradycardia (which
might progress to asystole) and atrial
ﬁbrillation to ventricular tachycardia.
RISKS OF HYPOGLYCEMIA
IN CRITICAL ILLNESS—Evidence
has emerged from other clinical studies of
people with serious illness to support the
premise that exposure to hypoglycemia
carries inherent CV risks. The mortality
rate of patients with diabetes, who were
exposed to severe hypoglycemia after ad-
mission to hospital with an acute coronary
syndrome, was twice that of those who did
not experience hypoglycemia (30). This
effect persisted after adjustment was
made for potential confounding factors
(31). In patients with ST-elevation acute
coronary syndrome, the 30-day mortality
was greater in patients at the upper and
lower (,4.5 mmol/L [81 mg/dL]) ex-
tremes of blood glucose measured on ad-
mission to hospitals, showing a U-shaped
curve (32). A similar pattern was observed
in patients with diabetes in the Japanese
Acute Coronary Syndrome Study, but not
in their nondiabetic group (33). In an-
other study, nondiabetic patients who de-
veloped spontaneous hypoglycemia while
in hospital had a poorer outcome and
a higher mortality than patients with
insulin-treated diabetes exposed to iatro-
genic hypoglycemia (34). Although the
development of hypoglycemia in this
situation may be a surrogate marker for
the severity of illness, it may also directly
contribute to a fatal outcome. The suscep-
tibility of those patients to a cardiac ar-
rhythmia may be increased by preceding
exposure to low blood glucose. Antecedent
hypoglycemia diminishes the cardiac vagal
baroreﬂex sensitivity and the sympathetic
response to drug-induced hypotension,
thus attenuating the autonomic responses
to CV stress for up to 16 h (28). This re-
sult may be a mechanism for inducing ar-
rhythmias, making the heart susceptible to
recurring hypoglycemia.
In a large multicenter randomized
controlled trial in Australia (NICE-
SUGAR) (35), the relationship of glyce-
mic control to outcome from critical
illness was examined in patients being
treated in intensive care units. Strict con-
trol of blood glucose (4.5–6.0 mmol/L)
was compared with standard control
(,10.0 mmol/L). Mortality was higher
in patients who maintained strict glyce-
mic control, in whom severe hypoglyce-
mia (deﬁned as blood glucose ,2.2
mmol/L) was much more common (6.8
vs. 0.5%; P, 0.001). A subgroup analysis
suggested that no difference in 90-day
mortality existed between individuals
with diabetes (;20%) and individuals
without diabetes (;80%). Potential weak-
nesses of this study limit interpretation.
Unfortunately, the protocol permitted a re-
duction in the frequency of blood glucose
measurements to four hourly tests when
blood glucose was considered to be “sta-
ble,”which was then inadequate to assess
glycemic control. In addition, neurogly-
copenia may be more difﬁcult to detect
in an unconscious patient under sedation
and may not therefore be identiﬁed. Two
meta-analyses (36,37) have shown that
strict glycemic control in seriously ill
patients does not improve overall sur-
vival but reduces the risk of septicemia
in surgical intensive care units at the
expense of a ﬁvefold higher incidence of
hypoglycemia (13.7 vs. 2.5%).
Alarming results have been reported
recently from a large multicenter registry
of 3,571 Japanese patients undergoing
ﬁrst elective coronary revascularization
(38) when a potential association was
examined between preoperative HbA1c
levels and the CV outcome. Of the 3,571
patients, 1,504 had type 2 diabetes; the
outcome in patients with type 2 diabetes
was analyzed according to four categories
of HbA1c: ,6%, 6 to ,7%, 7 to , 8%,
and .8%. Freedom from composite
events of CVD death, myocardial infarc-
tion, and stroke after coronary revascular-
ization was similar in nondiabetic patients
and in those diabetic patients presenting
with an HbA1c between 6 and 7%. By con-
trast, diabetic patients with higher HbA1c
values (7–8 and.8%) had a signiﬁcantly
higher rate of the composite end point
versus nondiabetic subjects (P ,
0.0005), but the composite end point of
CVD death, myocardial infarction, and
stroke after coronary revascularization
was similar or even higher in diabetic pa-
tients who had the lowest HbA1c values
(,6.0%) compared with those patients
with the poorest glycemic control.
GLYCEMIC CONTROL AND
LONG-TERM SURVIVAL—Out-
side the hospital setting, circumstantial
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evidence suggests that strict glycemic
control, with its greater risk of severe
hypoglycemia, may carry a potential risk
to long-term survival. A study using the
large U.K. General Practice Research
Database (39) examined the relationship
between HbA1c and survival using data
collected for .20 years from 48,000 pa-
tients with type 2 diabetes. One cohort
(n = 27,965) had been changed from
oral monotherapy to a combination of
oral medications, whereas the other co-
hort (n = 20,005) had commenced regi-
mens that included insulin. The primary
outcome measure of all-cause mortality
was examined for each decile of HbA1c
in both cohorts. The 10% of patients
who had the lowest HbA1c values
(,6.7%) had a higher mortality than all
other deciles with higher HbA1c values,
with the exception of the 10% with the
highest HbA1c values ($9.9%). The ad-
justed hazard ratios (HRs) for all-cause
mortality by HbA1c deciles showed a
U-shaped curve, irrespective of how or
when HbA1c was measured. This study
was criticized in that the patients in the
second cohort were older and the causes
of death were unknown. Also, the fre-
quency of hypoglycemia could not be de-
termined in this retrospective analysis.
Nevertheless, the greatest risk of death
and of cardiac events was associated
with the lowest and highest HbA1c values.
Although this evidence for a CV risk of
hypoglycemia is much more circumstan-
tial, this study supports the recommen-
dation that glycemic control must be
tailored to the age of the individual pa-
tient and in particular should address
his or her existing comorbidities and the
type of treatment to be used.
HYPOGLYCEMIA IN ACCORD,
ADVANCE, AND VADT—CVD is
the predominant cause of death in pa-
tients with type 2 diabetes, and reducing
the risk of CVD has recently been the fo-
cus of three large glucose-lowering trials:
ACCORD (Action to Control Cardiovas-
cular Risk in Diabetes) (4), ADVANCE
(Action in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled
Evaluation) (5), and VADT (Veterans Af-
fairs Diabetes Trial) (6) (Table 1). These
three studies randomized almost 24,000
patients with longstanding high-risk
type 2 diabetes to standard or intensive
glycemic control for up to 5 years, ensur-
ing HbA1c levels ,7%. Mean HbA1c
levels in the intensive arms of ACCORD,
ADVANCE, and VADT were 6.4, 6.5, and
6.9% in contrast to 7.5, 7.3, and 8.5% in
the standard arms. Unfortunately, strict
glycemic control in these three studies
did not incur a signiﬁcant CV beneﬁt,
and none of the trials demonstrated any
positive effect on CV events or mortality
(Table 1). Even worse, the ACCORD
study was prematurely interrupted be-
cause of an excess mortality among inten-
sively treated patients. The rate of death
from CV causes was higher in the inten-
sive therapy group than in the standard
therapy group (2.6 vs. 1.8%; HR 1.35;
95% CI 1.04–1.76; P = 0.02). Similarly,
the rate of death from any cause was also
signiﬁcantly higher in the intensive ther-
apy group than in the standard therapy
group (5.0 vs. 4.0%; HR 1.22; 95% CI
1.01–1.46; P = 0.04).
In all three trials, severe hypogly-
cemia was signiﬁcantly higher in the
intensive glucose-lowering arms com-
pared with the standard arms: ACCORD
16.2 vs. 5.1%; VADT 21.2 vs. 9.9%;
ADVANCE 2.7 vs. 1.5% (Fig. 2). The
much lower risk for severe hypoglycemia
in ADVANCE may be explained by the
fact that the patients in that trial appeared
to have earlier or less advanced diabetes,
with a shorter duration by 2–3 years and
lower HbA1c at entry despite very little use
of insulin at baseline (40). In addition, the
need for insulin treatment in the intensive
arm of ADVANCE was much lower com-
pared with that in the intensive arms of the
other two trials (Fig. 1).
Several post hoc analyses (41–44)
have now been reported by the ACCORD
investigators, who were unable to ascer-
tain the underlying causes of the higher
mortality rate associated with strict gly-
cemic control. Symptomatic severe hypo-
glycemia was associated with an increased
risk of death within each study arm. Un-
adjusted annual mortality among patients
in the intensive glucose control arm was
Table 1—Clinical characteristics and effects of intensive glucose lowering vs. standard
therapy on primary CV end point, total mortality, and CV mortality in ACCORD,
ADVANCE, and VADT
ACCORD ADVANCE VADT
n 10,251 11,140 1,791
Age (years) 62 66 60
Men/women (%) 61/39 58/42 97/3
Duration of study (years) 3.5 5.0 5.6
BMI (kg/m2) 32.2 6 5.5 28.0 6 5.0 31.3 6 3.5
Duration of diabetes (years) 10 8 11.5
CVD 35% 32% 40%
Primary CVD end point ↓10% (P = 0.16) ↓6% (P = 0.37) ↓13% (P = 0.12)
Mortality (overall) ↑22% (P = 0.04) ↓7% (P = NS) ↑6.5% (P = NS)
CV mortality ↑35% (P = 0.02) ↓12% (P = NS) ↑25% (P = NS)
Figure 2—Percentage of severe hypoglycemic events in ACCORD, ADVANCE, and VADT.
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2.8% in patients who had one or more
episodes of hypoglycemia requiring any
assistance compared with 1.2% for indi-
viduals with no episodes (53 deaths per
1,924 person-years and 201 deaths per
16,315 person-years, respectively; ad-
justed HR 1.41, 95% CI 1.03–1.93). A
similar pattern was seen among partici-
pants in the standard glucose control
arm (3.7% [21 deaths per 564 person-
years] vs. 1.0% [176 deaths per 17,297
person-years]; adjusted HR 2.30, 95%
CI 1.46–3.65). However, among partici-
pants who experienced at least one epi-
sode of hypoglycemia, the risk of death
was lower in participants in the intensive
arm than in the standard arm. Thus, the
ACCORD investigators concluded that
symptomatic severe hypoglycemia does
not appear to account for the difference
in mortality between the two arms of the
study up to the time when the ACCORD
intensive glycemia arm was discontinued
(43).
Nevertheless, it remains biologically
plausible that severe hypoglycemia could
increase the risk of CV death in partic-
ipants with high underlying CVD. This
risk might be further confounded by
the development of impaired awareness
of hypoglycemia, particularly in patients
with coexisting CV autonomic neuropa-
thy, a strong risk factor for sudden death.
A recent analysis from ACCORD (44)
conﬁrmed that patients with baseline
cardiac autonomic neuropathy were
about twice as likely to die as patients
without cardiac autonomic neuropathy.
The contribution of hypoglycemia to
the increased mortality in the intensive
study arm might be difﬁcult to identify
in large studies such as ACCORD. Death
from a hypoglycemic event may be mis-
takenly ascribed to coronary heart dis-
ease, since there may not have been a
preceding blood glucose measurement
and since hypoglycemia cannot be de-
tected postmortem.
In contrast to the ACCORD study, in
VADT, a recent severe hypoglycemic
event was an important predictor for CV
death (HR 3.72; 95% CI 1.34–10.4; P ,
0.01) and all-cause mortality (HR 6.37;
95%CI 2.57–15.8; P = 0.0001) as reported
by Dr. William Duckworth and col-
leagues at the American Diabetes Associ-
ation Scientiﬁc Sessions in 2009 in New
Orleans, Louisiana. By contrast, in the
ADVANCE study (5), in which the overall
occurrence of severe hypoglycemia was
much lower than in ACCORD, no in-
crease in all-cause or CV mortality was
observed in patients randomized to the
intensive arm. Nevertheless, severe hypo-
glycemia was strongly associated with
increased risks of various adverse clinical
outcomes (45), and the authors suggested
that whereas severe hypoglycemia may
contribute to these outcomes, it may alter-
natively be a marker of vulnerability to
these events.
Many patients with advanced diabetes
and CVD undergo coronary revasculariza-
tion. Detailed ﬁndings about the impact of
glycemic control on the outcome of the
patients in that situation have not yet been
reported in any of the three studies. Most
guidelines recommend HbA1c targets be-
low 7.0 or 6.5%, but without reference to
speciﬁc antidiabetes treatments, diabetes
duration, age of the patients, or preexisting
CVD (46). Because, according to a recent
meta-analysis, the beneﬁcial effect of strict
glycemic control on CV events (47) seems
to be limited for patients who are free from
CVD, a less stringent glycemic target
should be recommended for diabetic pa-
tients with longer duration of the disease,
shorter life expectancy, advanced macro-
vascular complications, and chronic kid-
ney disease and patients who are prone
to hypoglycemia (46,47). Accordingly, fu-
ture diabetes guidelines will have to
deﬁne a minimumHbA1c value, especially
for patients with longstanding diabetes
or who have established CVD (46). In-
discriminate application of intensive
glucose-lowering therapy that could pro-
voke dangerous hypoglycemia in frail
elderly people with type 2 diabetes, or
in patients with overt CVD, should be
avoided.
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